CHRS Q1 2024 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-92.9% YoY

Gross Profit

$869,00037.7% margin

Operating Income

-$68M-2937.0% margin

Net Income

$103M4457.3% margin

EPS (Diluted)

$0.82

QoQ Revenue Growth

-97.5%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$47M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$764M

Total Liabilities

$845M

Stockholders' Equity

-$82M

Cash & Equivalents

$260M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$32M	-92.9%
Gross Profit	$869,000	$16M	-94.4%
Operating Income	-$68M	-$68M	-0.1%
Net Income	$103M	-$76M	+235.8%

Revenue Segments

Product Revenue

$77M100%

Other

$320,0000%